Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Molecular Imaging and Biology
Published in: Molecular Imaging and Biology 5/2008

01-09-2008 | Research Article

NCI-Sponsored Trial for the Evaluation of Safety and Preliminary Efficacy of FLT as a Marker of Proliferation in Patients with Recurrent Gliomas: Safety Studies

Authors: Alexander M. Spence, Mark Muzi, Jeanne M. Link, John M. Hoffman, Janet F. Eary, Kenneth A. Krohn

Published in: Molecular Imaging and Biology | Issue 5/2008

Login to get access

Abstract

Purpose

3’-[F-18]Fluoro-3’-deoxythymidine (FLT) is an analog of thymidine that is being developed for imaging cellular proliferation. The goal of this study was to prove that the dose of FLT used for positron emission tomography imaging produces no significant toxicity.

Procedures

Twelve patients with gliomas with either recurrence or suspected radionecrosis were imaged with FLT. Before and at several time points after imaging, subjects underwent general physical and neurological examinations with review of systems and tests of hematologic, hepatic, renal, and several other metabolic parameters. Vital signs and electrocardiograms were monitored during and after the imaging session.

Results

There were no significant adverse effects from FLT injected at a dose of 0.07 mCi/kg (maximum of 5 mCi) at specific activities of 1.25 Ci/μmol or higher. The FLT mass administered for imaging was 0.0001% to 0.0009% of the least toxic cumulative dose administered in clinical trials of FLT as an antiretroviral agent.

Conclusions

FLT is a safe radiotracer for quantifying proliferation in the human cancer setting.
Literature
1.
Grierson JR, Shields AF (2000) Radiosynthesis of 3’-deoxy-3’- [(18)F]fluorothymidine: [(18)F]FLT for imaging of cellular proliferation in vivo. Nucl Med Biol 27:143–156PubMedCrossRef
2.
Shields AF, Grierson JR, Dohmen BM, et al. (1998) Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat Med 4:1334–1336PubMedCrossRef
3.
Grierson JR, Schwartz JL, Muzi M, Jordan R, Krohn KA (2004) Metabolism of 3’-deoxy-3’-[F-18]fluorothymidine in proliferating A549 cells: validations for positron emission tomography. Nucl Med Biol 31:829–837PubMedCrossRef
4.
Langen P, Etzold G, Hintsche R, Kowollik G (1969) 3’-Deoxy-3’-fluorothymidine, a new selective inhibitor of DNA-synthesis. Acta Biol Med Ger 23:759–766PubMed
5.
Langen P, Graetz H (1972) Cell death resulting from inhibition by 3’-deoxy-3’-fluorothymidine, cytosine-arabinoside, 5-fluoro-2’- deoxyuridine, and hydroxyurea of DNA synthesis in cultured Ehrich ascites carcinoma cells. Studia Biophys 31/32:359–366
6.
Langen P, Kowollik G, Etzold G, Venner H, Reinert H (1972) The phosphorylation of 3’-deoxy-3’-fluorothymidine and its incorporation into DNA in a cellfree system from tumor cells. Acta Biol Med Ger 29:483–494PubMed
7.
Matthes E, Lehmann C, Scholz D, Rosenthal HA, Langen P (1988) Phosphorylation, anti-HIV activity and cytotoxicity of 3’-fluorothymidine. Biochem Biophys Res Commun 153:825–831PubMedCrossRef
8.
Faraj A, Fowler DA, Bridges EG, Sommadossi JP (1994) Effects of 2’,3’-dideoxynucleosides on proliferation and differentiation of human pluripotent progenitors in liquid culture and their effects on mitochondrial DNA synthesis. Antimicrob Agents Chemother 38:924–930PubMed
9.
Flexner C, van der Horst C, Jacobson MA, et al. (1994) Relationship between plasma concentrations of 3’-deoxy-3’-fluorothymidine (alovudine) and antiretroviral activity in two concentration-controlled trials. J Infect Dis 170:1394–1403PubMed
10.
Matthes E, Lehmann C, Scholz D, et al. (1987) Inhibition of HIV-associated reverse transcriptase by sugar-modified derivatives of thymidine 5’-triphosphate in comparison to cellular DNA polymerases alpha and beta. Biochem Biophys Res Commun 148:78–85PubMedCrossRef
11.
Sundseth R, Joyner SS, Moore JT, Dornsife RE, Dev IK (1996) The anti-human immunodeficiency virus agent 3’-fluorothymidine induces DNA damage and apoptosis in human lymphoblastoid cells. Antimicrob Agents Chemother 40:331–335PubMed
12.
Turcotte E, Wiens LW, Grierson JR, Peterson LM, Wener MH, Vesselle H (2007) Toxicology evaluation of radiotracer doses of 3’-deoxy-3’-[18F]fluorothymidine (18F-FLT) for human PET imaging: laboratory analysis of serial blood samples and comparison to previously investigated therapeutic FLT doses. BMC Nucl Med 7:3 ElectronicPubMedCrossRef
13.
Muzi M, Spence AM, O’Sullivan F, et al. (2006) Kinetic analysis of 3’-deoxy-3’-18F-fluorothymidine in patients with gliomas. J Nucl Med 47:1612–1621PubMed
14.
Graham MM, Lewellen BL (1993) High-speed automated discrete blood sampling for positron emission tomography. J Nucl Med 34:1357–1360PubMed
15.
Lewellen TK, Kohlmyer SG, Miyaoka RS, Kaplan MS, Stearns CW, Schubert SF (1996) Investigation of the performance of the General Electric ADVANCE positron emission tomograph in 3D mode. IEEE Trans Nucl Sci 43:2199–2206CrossRef
16.
Kinahan PE, Townsend DW, Beyer T, Sashin D (1998) Attenuation correction for a combined 3D PET/CT scanner. Med Phys 25:2046–2053PubMedCrossRef
17.
Lundgren B, Bottiger D, Ljungdahl-Stahle E, et al. (1991) Antiviral effects of 3’-fluorothymidine and 3’-azidothymidine in cynomolgus monkeys infected with simian immunodeficiency virus. J Acquir Immune Defic Syndr 4:489–498PubMed
18.
Muzi M, Mankoff DA, Grierson JR, Wells JM, Vesselle H, Krohn KA (2005) Kinetic modeling of 3’-deoxy-3’-fluorothymidine in somatic tumors: mathematical studies. J Nucl Med 46:371–380PubMed
19.
Graham MM (1997) Physiologic smoothing of blood time-activity curves for PET data analysis. J Nucl Med 38:1161–1168PubMed
Metadata
Title
NCI-Sponsored Trial for the Evaluation of Safety and Preliminary Efficacy of FLT as a Marker of Proliferation in Patients with Recurrent Gliomas: Safety Studies
Authors
Alexander M. Spence
Mark Muzi
Jeanne M. Link
John M. Hoffman
Janet F. Eary
Kenneth A. Krohn
Publication date
01-09-2008
Publisher
Springer-Verlag
Published in
Molecular Imaging and Biology / Issue 5/2008
Print ISSN: 1536-1632
Electronic ISSN: 1860-2002
DOI
https://doi.org/10.1007/s11307-008-0151-6

Other articles of this Issue 5/2008

Molecular Imaging and Biology 5/2008 Go to the issue

Research Article

2-Deoxy-2[F-18]FDG-PET for Detection of Recurrent Laryngeal Carcinoma after Radiotherapy: Interobserver Variability in Reporting

Research Article

11C-Acetate PET in the Evaluation of Brain Glioma: Comparison with 11C-Methionine and 18F-FDG-PET

Research Article

Basic Evaluation of FES-hERL PET Tracer-Reporter Gene System for In Vivo Monitoring of Adenoviral-Mediated Gene Therapy

Research Article

Perfluorohexane-loaded Macrophages as a Novel Ultrasound Contrast Agent: A Feasibility Study

Brief Article

Usefulness of Automatic Quantification of Immunochemical Staining on Whole Tumor Sections for Correlation with Oncological Small Animal PET Studies: An Example with Cell Proliferation, Glucose Transporter 1 and FDG

Rapid Communication

Design and Fabrication of Phantoms Using Stereolithography for Small-Animal Imaging Systems